|
Variable
|
Disease-free survival
|
Overall survival
|
|---|
| |
P value
|
Relative risk (95% CI)
|
P value
|
Relative risk (95% CI)
|
|---|
|
Tumor grade
|
0.0201
|
1.767 (1.093 to 2.86)
|
0.0072
|
1.785 (1.170 to 2.725)
|
|
Tumor size
|
0.0007
|
2.070 (1.357 to 3.160)
|
0.0052
|
1.662 (1.164 to 2.375)
|
|
Nodal status
|
<0.0001
|
3.193 (2.091 to 4.876)
|
<0.0001
|
2.205 (1.545 to 3.148)
|
|
HER2
|
0.0037
|
2.470 (1.342 to 4.546)
|
0.0595
|
1.739 (0.978 to 3.093)
|
|
pHER1
|
0.0346
|
1.683 (1.038 to 2.726)
|
0.2317
|
1.309 (0.842 to 2.033)
|
|
pHER2
|
<0.0001
|
2.699 (1.662 to 4.384)
|
0.0002
|
2.273 (1.470 to 3.513)
|
|
pHER3
|
0.0489
|
1.686 (1.002 to 2.835)
|
0.3926
|
1.233 (0.763 to 1.995)
|
|
HER4
|
<0.0001
|
0.361 (0.238 to 0.549)
|
0.0111
|
0.624 (0.433 to 0.898)
|
- Variables were analyzed as follows: tumor grade (1 and 2 vs. 3), tumor size (<25 mm vs. ≥ 25 mm), nodal status (0 vs. ≥ 1), HER2 (negative vs. positive), pHER1 (negative vs. positive), pHER2 (negative and weak vs. strong), pHER3 (negative vs. positive), HER4 (low vs. high). 95% CI, 95% confidence interval. Bold data represent significant values.
